HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ballas, S. K. Search for Related Content PubMed PubMed Citation Articles by Ballas, S. K. Social Bookmarking                   What's this?

Current Issues in Sickle Cell Pain and Its Management

Correspondence: Samir K. Ballas, MD, Cardeza Foundation, 1015 Walnut Street, Philadelphia PA 19107; phone:215-955-8485; fax 215-923-7859; samir.ballas{at}mail.tju.edu

Abstract

Pain is the insignia of sickle cell disease and the acute painful crisis is the number-one cause of hospital admissions. Tissue damage due to vaso-occlusion releases numerous inflammatory mediators that initiate the transmission of painful stimuli and the perception of pain. The acute sickle cell painful crisis evolves along four distinct phases coupled with changes in certain markers of the disease. Hospital readmission within 1 week occurs in about 16% of discharged patients. Failure to treat acute pain aggressively may lead to chronic pain syndrome. Management of sickle pain is primarily pharmacologic in nature, and opioids are the analgesics used most often. Cellular and molecular mechanisms of opioids explain individual differences among patients and justify the use of individualized treatment plans.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?